Thai, U.S. Trade Meeting Set Over Compulsory License Policy
This article was originally published in PharmAsia News
Thailand's Commerce Ministry permanent secretary scheduled a meeting with a U.S. Trade Representative official March 17 on the Asian nation's compulsory licensing policy on drug patents. The United States is to decide by the end of April whether to take Thailand off its Priority Watch List for countries that violate global intellectual property protection rules. Thai Commerce Minister Mingkwan Sangsuwan also is set to meet with USTR head Susan Schwab next month in Bangkok. Several Thai ministries are to decide this week on the status of the CL policy. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?